We are applying our precision, RNA-based biomarker approach to improve patient outcomes

Oncologie is deploying its proprietary, precision, RNA-based biomarker platform to dramatically improve patient outcomes through careful patient selection and clinical trial design with next-generation biologics. Our current portfolio of programs targets the tumor microenvironment and our teams in Boston and Shanghai are working together to bring our new therapies and innovative approach closer to patients.

We are applying our precision, RNA-based biomarker approach to improve patient outcomes

Oncologie is deploying its proprietary, precision, RNA-based biomarker platform to dramatically improve patient outcomes through careful patient selection and clinical trial design with next-generation biologics. Our current portfolio of programs targets the tumor microenvironment and our teams in Boston and Shanghai are working together to bring our new therapies and innovative approach closer to patients.

Bavituximab

Learn More

Bavituximab Overview

Bavituximab is an investigational monoclonal antibody that blocks activation of immunomodulatory TAM and TIM receptors on immune cells by phosphatidylserine (PS).

Navicixizumab

Learn More

Navicixizumab Overview

Navicixizumab is an investigational bi-specific antibody that inhibits the activity of both vascular endothelial growth factor A (VEGF-A) and delta-like ligand 4 (DLL4), two pathways identified in playing a role in tumor progression.

Varisacumab

Learn More

Varisacumab Overview

Varisacumab is an investigational monoclonal antibody that binds to the vascular endothelial growth factor (VEGFA) and selectively inhibits the activation of VEGF receptor 2 (VEGFR-2).